Locations:
Search IconSearch
April 4, 2018/Cancer/News & Insight

Social Media and Journal Clubs: The Ultimate Peer Review?

An oncologist weighs in

social-media_650x450

ByAaron Gerds, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Cotton Club, The Breakfast Club and journal club. Like other legendary clubs, journal club has centered around an in-person gathering to facilitate the exchange of commentary and ideas on a given topic. The critical evaluation of recent articles conducted in journal clubs serves as a building block for medical education, evidence-based guidelines and quality improvement initiatives. From residency training, I have very vivid — dare I say fond? — memories of journal club at Hines VA Hospital getting into the nitty gritty of numbers needed to treat with then Chairman Brian Schmitt, MD, MPH. For the past 180 years, from Sir James Paget to Gordon Guyatt, MD, MSc, journal clubs have been steadfast with a very gradual evolution, but the technology revolution is shaking things up.

Social media, including Twitter, has changed the way we communicate. In addition to focused composition and the introduction of emoji, it has also eliminated distance and time. Discussions including thousands can be had instantly across the globe. It has been argued that social media has dumbed down discourse, reducing it to a series of likes or retweets. Despite its limitations, it can be a powerful tool in the appraisal of the medical literature.

With most manuscripts posted on publishers’ websites well in advance of print, the peer review process can occur almost instantaneously. Social media also enables the readership to interact directly with the authors.

With such a large volume of users, critiques presented and validated are essentially crowdsourced, and conversely, individuals can provide insight on how local context may affect the application of results in their own practice. Social media invites its users to come off the bench and get into the game, identifying quality and refuting misinterpretation by a simple post for many, with others taking the next step into content creation. One key element yet to be clarified as things move forward is how these contributions will be measured and how faculty will get academic credit for participating in online forums.

Advertisement

While time will tell if Twitter and social media are the ultimate peer review, it is clear that they can be a powerful tool in conducting academic medicine. I wonder if William Osler would share his critiques in 280 characters or less.

Dr. Gerds is a staff physician in the Department of Hematology and Medical Oncology and publishes in medical literature about social media use. Follow him on Twitter @AaronGerds.

Advertisement

Related Articles

Dr. Khorana
April 25, 2025/Cancer/News & Insight
Molecular Insights into Early-Onset Biliary Tract Cancer (Podcast)

A call for awareness about the importance of genomic testing

Dr. Melenhorst
April 24, 2025/Cancer/News & Insight
Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Dr. Cherian
April 23, 2025/Cancer/News & Insight
De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight
Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight
Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Dr. Gerds with a patient
April 7, 2025/Cancer/News & Insight
Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Baby's feet
April 3, 2025/Cancer/News & Insight
Fertility Preservation Counseling for Young Adults with Cancer

Growing need for addressing fertility concerns

Ad